Dr. Scott E. Kasner, MD
Neurology (Vascular Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 115
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: Yale University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Vascular Neurology Physician primary
PA license MD053803L -
Neurology Physician
PA license MD053803L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hospital of Univ of Pennsylvania Philadelphia, PA
Medical groups
- University of Penn - Medical Group (3,505 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 115
- Services billed
- 254
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 63 | 54 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 36 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 17 | 11 |
| Established patient office or other outpatient visit, 40-54 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Philadelphia, PA | 24 |
| Donepezil Hcl Other prescribers in Philadelphia, PA | 24 |
| Atorvastatin Calcium Other prescribers in Philadelphia, PA | 13 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Philadelphia, PA | 13 |
| Amlodipine Besylate Other prescribers in Philadelphia, PA | 12 |
| Xarelto (rivaroxaban) Other prescribers in Philadelphia, PA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 39 payments worth $33,676 in total to this clinician.
| Shionogi Inc | $10,054 |
|---|---|
| Abbott Laboratories | $7,474 |
| Bayer HealthCare Pharmaceuticals Inc. | $7,367 |
| AstraZeneca Pharmaceuticals LP | $4,500 |
| W. L. Gore & Associates, Inc. | $2,813 |
| Artivion, Inc. | $1,300 |
| Medtronic, Inc. | $169 |
| Consulting Fee | $31,065 |
|---|---|
| Travel and Lodging | $1,825 |
| Food and Beverage | $786 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Shionogi Inc Apr 11, 2025 | Consulting Fee S-005151 · Neurology | $7,560 |
| Abbott Laboratories Apr 10, 2025 | Consulting Fee AMPLATZER TALISMAN · Structural Heart | $5,375 |
| Bayer HealthCare Pharmaceuticals Inc. Feb 3, 2025 | Consulting Fee | $2,935 |
| Shionogi Inc Oct 10, 2025 | Consulting Fee S-005151 · Neurology | $2,494 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 4, 2025 | Consulting Fee | $2,328 |
| Bayer HealthCare Pharmaceuticals Inc. May 12, 2025 | Consulting Fee | $1,761 |
| AstraZeneca Pharmaceuticals LP May 22, 2025 | Consulting Fee | $1,350 |
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Consulting Fee | $1,225 |
| AstraZeneca Pharmaceuticals LP Oct 29, 2025 | Consulting Fee | $1,050 |
| Abbott Laboratories Mar 19, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $939 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Consulting Fee | $1,225 |
| AstraZeneca Pharmaceuticals LP Oct 29, 2025 | Consulting Fee | $1,050 |
| W. L. Gore & Associates, Inc. Oct 24, 2025 | Consulting Fee Product in Development · Devices | $638 |
| W. L. Gore & Associates, Inc. Oct 24, 2025 | Consulting Fee Product in Development · Devices | $383 |
| Artivion, Inc. Oct 23, 2025 | Consulting Fee AMDS-Ascyrus Medical · Cardiovascular and vascular surgery | $700 |
| Shionogi Inc Oct 10, 2025 | Consulting Fee S-005151 · Neurology | $2,494 |
| W. L. Gore & Associates, Inc. Oct 3, 2025 | Consulting Fee Product in Development · Devices | $893 |
| Bayer HealthCare Pharmaceuticals Inc. Sep 4, 2025 | Consulting Fee | $2,328 |
| Artivion, Inc. Aug 14, 2025 | Consulting Fee AMDS-Ascyrus Medical · Cardiovascular and vascular surgery | $600 |
| AstraZeneca Pharmaceuticals LP Jun 5, 2025 | Consulting Fee | $525 |
| AstraZeneca Pharmaceuticals LP May 22, 2025 | Consulting Fee | $1,350 |
| Bayer HealthCare Pharmaceuticals Inc. May 12, 2025 | Consulting Fee | $1,761 |
| AstraZeneca Pharmaceuticals LP Apr 28, 2025 | Consulting Fee | $350 |
| Shionogi Inc Apr 11, 2025 | Consulting Fee S-005151 · Neurology | $7,560 |
| Abbott Laboratories Apr 10, 2025 | Consulting Fee AMPLATZER TALISMAN · Structural Heart | $5,375 |
| Abbott Laboratories Apr 10, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $56.00 |
| W. L. Gore & Associates, Inc. Mar 28, 2025 | Consulting Fee Product in Development · Devices | $900 |
| Abbott Laboratories Mar 19, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $939 |
| Abbott Laboratories Mar 19, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $9.02 |
| Abbott Laboratories Mar 17, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $240 |
| Abbott Laboratories Mar 16, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $256 |
| Abbott Laboratories Mar 16, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $162 |
| Abbott Laboratories Mar 16, 2025 | Travel and Lodging AMPLATZER TALISMAN · Structural Heart · travel to Minneapolis, MN · in-kind | $162 |
| Bayer HealthCare Pharmaceuticals Inc. Feb 3, 2025 | Consulting Fee | $2,935 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $374,098 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.